These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 27351133)
1. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer. Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133 [TBL] [Abstract][Full Text] [Related]
2. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. Kumarasamy VM; Shin YJ; White J; Sun D BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103 [TBL] [Abstract][Full Text] [Related]
3. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. Kumarasamy VM; Sun D Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409 [TBL] [Abstract][Full Text] [Related]
4. Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells. Shin YJ; Kumarasamy V; Camacho D; Sun D Oncogene; 2015 Mar; 34(10):1292-9. PubMed ID: 24662821 [TBL] [Abstract][Full Text] [Related]
5. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586 [TBL] [Abstract][Full Text] [Related]
6. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748 [TBL] [Abstract][Full Text] [Related]
7. Naphthalene diimide-derivatives G-quadruplex ligands induce cell proliferation inhibition, mild telomeric dysfunction and cell cycle perturbation in U251MG glioma cells. Muoio D; Berardinelli F; Leone S; Coluzzi E; di Masi A; Doria F; Freccero M; Sgura A; Folini M; Antoccia A FEBS J; 2018 Oct; 285(20):3769-3785. PubMed ID: 30095224 [TBL] [Abstract][Full Text] [Related]
8. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696 [TBL] [Abstract][Full Text] [Related]
9. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037 [TBL] [Abstract][Full Text] [Related]
11. Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system. Okamoto M; Yoshioka Y; Maeda K; Bito Y; Fukumoto T; Uesaka T; Enomoto H Genesis; 2019 May; 57(5):e23292. PubMed ID: 30884088 [TBL] [Abstract][Full Text] [Related]
12. The importance of the RET gene in thyroid cancer and therapeutic implications. Salvatore D; Santoro M; Schlumberger M Nat Rev Endocrinol; 2021 May; 17(5):296-306. PubMed ID: 33603219 [TBL] [Abstract][Full Text] [Related]
13. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Drosten M; Stiewe T; Pützer BM Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215 [TBL] [Abstract][Full Text] [Related]
14. Precision Targeted Therapy with BLU-667 for Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135 [TBL] [Abstract][Full Text] [Related]
15. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer. Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694 [TBL] [Abstract][Full Text] [Related]
16. Structural basis for telomeric G-quadruplex targeting by naphthalene diimide ligands. Collie GW; Promontorio R; Hampel SM; Micco M; Neidle S; Parkinson GN J Am Chem Soc; 2012 Feb; 134(5):2723-31. PubMed ID: 22280460 [TBL] [Abstract][Full Text] [Related]
17. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells. Nicolini V; Cassinelli G; Cuccuru G; Bongarzone I; Petrangolini G; Tortoreto M; Mondellini P; Casalini P; Favini E; Zaffaroni N; Zunino F; Lanzi C Biochem Pharmacol; 2011 Oct; 82(7):778-88. PubMed ID: 21741956 [TBL] [Abstract][Full Text] [Related]
18. Targeting pancreatic cancer with a G-quadruplex ligand. Gunaratnam M; de la Fuente M; Hampel SM; Todd AK; Reszka AP; Schätzlein A; Neidle S Bioorg Med Chem; 2011 Dec; 19(23):7151-7. PubMed ID: 22041170 [TBL] [Abstract][Full Text] [Related]
19. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007 [TBL] [Abstract][Full Text] [Related]
20. MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET. Duan L; Hao X; Liu Z; Zhang Y; Zhang G FEBS Lett; 2014 May; 588(9):1644-51. PubMed ID: 24631532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]